Skip to main content
Premium Trial:

Request an Annual Quote

DiscoveryBioMed to Conduct Bioassay Testing for Lifeline

NEW YORK (GenomeWeb News) – DiscoveryBioMed today said that it has inked a service contract with Lifeline Cell Technology to conduct primary human cell bioassay testing for the subsidiary of International Stem Cell Corp.

The contract partners DBM's expertise in assay development with Lifeline's expertise in producing optimized human adult and stem cell products, said Lifeline CEO Jeffrey Janus.

Birmingham, Ala.-based DBM also said that the partners are developing a mutual Small Business Innovation Research grant proposal based on using multiple human cell cultures derived from different tissues as an in vitro platform for testing pollutant, candidate therapeutics and existing drugs for toxicity against cells.

Financial and other terms of the contract were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.